Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: The choice and schedule of fluoropyrimidine matters Review uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Colorectal Neoplasms
  • Proto-Oncogene Proteins
  • ras Proteins

abstract

  • The lack of benefit for cetuximab with capecitabine/bolus 5-FU regimens is unexpected. Cetuximab should only be used with infusional 5-FU regimens in the first-line treatment of K-ras WT colorectal cancer patients. Further study is urgently needed to elucidate the basis of this observation.

publication date

  • August 2012

Research

keywords

  • Review

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1007/s00280-012-1898-7

PubMed ID

  • 22699811

Additional Document Info

start page

  • 231

end page

  • 8

volume

  • 70

number

  • 2